Compare HUM & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUM | IQV |
|---|---|---|
| Founded | 1961 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Medical Specialities | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.1B | 43.1B |
| IPO Year | 2002 | 2013 |
| Metric | HUM | IQV |
|---|---|---|
| Price | $457.54 | $265.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 26 | 20 |
| Target Price | ★ $494.25 | $311.89 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 11-06-2026 | 10-27-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | ★ 16.84 | 5.24 |
| Revenue | ★ $129,664,000,000.00 | $9,739,000,000.00 |
| Revenue This Year | $25.64 | $7.18 |
| Revenue Next Year | $5.94 | $6.34 |
| P/E Ratio | ★ $26.64 | $50.84 |
| Revenue Growth | 10.11 | ★ 41.60 |
| 52 Week Low | $163.11 | $154.50 |
| 52 Week High | $456.50 | $284.50 |
| Indicator | HUM | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 65.62 | 46.99 |
| Support Level | $397.36 | $252.49 |
| Resistance Level | N/A | $274.49 |
| Average True Range (ATR) | 17.54 | 9.24 |
| MACD | 3.04 | -0.63 |
| Stochastic Oscillator | 95.34 | 44.74 |
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.